Search | Clinical Trials Finder

Conditions: Acute Pain
Interventions: VX-150, HB/APAP, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, California + 1 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator; Drug · Other
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more

Conditions: SARS CoV 2 Infection
Interventions: EDP-235, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Diabetes Mellitus, Type 2, Hypoglycemia
Interventions: FreeStyle Libre 2 CGM, FreeStyle Libre Pro blinded CGM, FreeStyle Precision Neo blood glucose meter; Device
Lead sponsor: Palo Alto Medical Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Palo Alto, California • Atlanta, Georgia

Conditions: Healthy Subjects
Interventions: MGD010, Placebo, Hepatitis A vaccine; Drug · Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 169
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more

Conditions: Glaucoma, Open-Angle
Interventions: H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]; Drug
Lead sponsor: Allysta Pharmaceutical; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Ankylosing Spondylitis
Interventions: Placebo, Bimekizumab; Other · Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Anniston, Alabama • La Jolla, California • Upland, California + 12 more

Conditions: Phenylketonurias
Interventions: sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 8 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 13
States / cities: Los Angeles, California • Oakland, California • New Haven, Connecticut + 10 more

Conditions: Long QT Syndrome
Interventions: GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 36
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more

Conditions: Papulopustular Rosacea (PPR)
Interventions: CD5024, Azelaic acid 15% Gel; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more

Conditions: Healthy Subjects
Interventions: TR-701, linezolid, placebo; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HiV1- Positive
Interventions: Abacavir/Lamivudine; Drug
Lead sponsor: Therapeutic Concepts; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rhinitis, Allergic
Interventions: Chlorpheniramine maleate (BAY X002134), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Psoriasis
Interventions: Anti IL-12 monoclonal antibody/ABT-874, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 16
States / cities: San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more

Conditions: Primary Hyperoxaluria
Interventions: Oxalobacter formigenes, Placebo; Biological · Drug
Lead sponsor: OxThera; Industry
Eligibility: 2 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Restless Legs Syndrome (RLS)
Interventions: gabapentin enacarbil, diphenhydramine, placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity
Interventions: DA-1726, Placebo to DA-1726; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Spinal Cord Injuries, Stroke, Lacunar, Stroke Brainstem, Cervical Spinal Cord Injury, Spinal Muscular Atrophy, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions: Motor Neuroprosthesis (MNP); Device
Lead sponsor: Synchron Medical, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Buffalo, New York • New York, New York • Pittsburgh, Pennsylvania

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 112
States / cities: Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more

Conditions: Moderate to Severe Asthma
Interventions: Spinal Cord Stimulation; Device
Lead sponsor: Spiro Medical, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • Gainesville, Florida • Orlando, Florida

Search by objective public record fields.

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

A Study of EDP-235 in Healthy Subjects

FreeStyle Libre 2 Discharge Trial

Phase 1 Study of MGD010 in Healthy Subjects

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

H-1337 Ophthalmic Solution Phase 1/2

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Phase 3 Papulopustular Rosacea Study

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy

Exploratory Study for Allergy Relief Onset

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2/3 Oxabact Study

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

First in Human Study in Subjects With Obesity, But Otherwise Healthy

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

PULmonary Stimulation for Asthma Relief